# Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

> **NCT01132586** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 61 (actual)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1
- Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL
- Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA
- Alkylating Agent-Related Acute Myeloid Leukemia
- de Novo Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Recurrent Adult Acute Myeloid Leukemia
- Secondary Acute Myeloid Leukemia
- Secondary Myelodysplastic Syndrome
- Untreated Adult Acute Myeloid Leukemia

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **OTHER:** Pharmacological Study
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01132586
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132586, "Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01132586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*